Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma by Haldar P

Get full text

Diagnosis and management of adult asthma by Haldar, P, Pavord, I

Noneosinophilic asthma: a distinct clinical and pathologic phenotype. by Haldar, P, Pavord, I

Diagnosis and management of adult asthma by Haldar, P, Pavord, I

A case of proptosis by Mathur K, Kulshreshtha R, Haldar P

Get full text

Diagnosis and Management of Asthma in Adults by Pavord, I, Green, R, Haldar, P

Dr. Pavord and colleagues reply by Pavord, I, Wardlaw, A, Haldar, P

Mepolizumab in refractory eosinophilic asthma. by Pavord, I, Haldar, P, Bradding, P, Wardlaw, A

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis by Haldar, P, Haldar, P, Brightling, C, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Gupta, S, Monteiro, W, Bradding, P, Bradding, P, Green, R, Wardlaw, A, Wardlaw, A, Ortega, H, Pavord, I

Cluster analysis and clinical asthma phenotypes. by Haldar, P, Pavord, I, Shaw, D, Berry, M, Thomas, M, Brightling, C, Wardlaw, A, Green, R

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma by Yancey, S, Ortega, H, Keene, O, Mayer, B, Gunsoy, N, Brightling, C, Bleecker, E, Haldar, P, Pavord, I

Qualitative analysis of high-resolution CT scans in severe asthma. by Gupta, S, Siddiqui, S, Haldar, P, Raj, J, Entwisle, J, Wardlaw, A, Bradding, P, Pavord, I, Green, R, Brightling, C

Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. by Gupta, S, Siddiqui, S, Haldar, P, Entwisle, J, Mawby, D, Wardlaw, A, Bradding, P, Pavord, I, Green, R, Brightling, C

Exacerbations of severe asthma in patients treated with mepolizumab by Shrimanker, R, Pavord, I, Yancey, S, Heaney, L, Green, R, Bradding, P, Hargadon, B, Brightling, C, Wardlaw, A, Haldar, P

Antieosinophil Therapeutics by Straumann, A, Haldar, P, Pavord, I, Wardlaw, A, Busse, W, Molfino, N, Kolbeck, R, Shin, M, Bochner, B, Cools, J

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma by Shrimanker, R, Hargaden, B, Bradding, P, Wardlaw, A, Brightling, C, Green, R, Bafadhel, M, Heaney, L, Pavord, I, Haldar, P

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo by Shrimanker, R, Hargaden, B, Bradding, P, Wardlaw, AJ, Brightling, CE, Green, R, Bafadhel, M, Pavord, ID, Haldar, P, Heaney, L

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. by Kulkarni, N, Hollins, F, Sutcliffe, A, Saunders, R, Shah, S, Siddiqui, S, Gupta, S, Haldar, P, Green, R, Pavord, I, Wardlaw, A, Brightling, C

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis by Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. by Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I